The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.
|Articles|April 15, 2003
- BioPharm International-04-01-2003
- Volume 16
- Issue 4
Virus Inactivation in the 1990s and into the 21st Century
by Gail Sofer, BioReliance Dorothy C. Lister, and Jeri Ann Boose Smallest of the microorganisms, viruses depend on other cells ? like those used by biopharmaceutical manufacturers ? for reproduction. And viruses and drug products are idiosyncratic: Both the inactivation process and the product strongly influence the successful outcome. In this conclusion to the virus inactivation series, model ivruses are used to represent single- and double-stranded DNA and RNA viruses, to enable you to reach conclusions about effective inactivation methods for a range of viruses.
Advertisement
Articles in this issue
over 23 years ago
Getting Ready for Risk-Based GMPsover 23 years ago
GMP Issues: Breaking Groundover 23 years ago
Guest Editorial: Benchmarking Biotechover 23 years ago
Optimized Nutrient Additives for Fed-Batch Culturesover 23 years ago
Inside Washington: GMP Progress ReportAdvertisement
Related to this article
Gilead agrees to acquire PepStar’s oral IL-23R peptide program for $1.275 billion, Zymeworks licenses its DLL3-targeted trispecific T-cell engager ZW209 to Roche, and the US Treasury proposes adding biotechnology to its outbound investment restrictions.
FNIH CEO Dr Julie Gerberding will open the October 25-28 meeting with a talk on using AI, adaptive trials, and alternative methods in drug development.
Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
Phase 1 HCXT-2001, an oral macrocyclic IL-23R peptide, could be paired with emvistegrast as a daily oral IBD treatment, according to Gilead.
Roche gains exclusive global rights to ZW209, a DLL3×CD3×CD28 trispecific T-cell engager designed for CD28 co-stimulation. A phase 1 study in small cell lung cancer and other neuroendocrine tumors is underway.
A Treasury proposed rule would restrict certain US investments in biotechnology in China and other countries of concern, raising questions about how cross-border licensing and joint venture deals will be treated.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Advertisement
Advertisement
Trending on BioPharm International
1
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
2
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy
5